Metraipolis › archive › dc_07ea80057def

Immunotherapy in Early Parkinson's Disease: A Biomarker-Driven Trial Framework for Secondary Prevention — Europe PMC PMID:41195411

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41195411
DOI
10.7759/cureus.96090
License (as archived)
solo-consultazione
Archived
2026-11-08T19:37:49.001Z
SHA-256 of the archived text
2ee903b5ffa9ac5063a90400da645ee13cb6180b2748aec8410be005ddddb647
Stable URL of this page
https://metraipolis.com/documento/dc_07ea80057def

How to cite

Immunotherapy in Early Parkinson's Disease: A Biomarker-Driven Trial Framework for Secondary Prevention — Europe PMC PMID:41195411 — Europe PMC (en), https://europepmc.org/article/MED/41195411 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_07ea80057def (Metraipolis archive dc_07ea80057def, sha256 2ee903b5ffa9ac5063a90400da645ee13cb6180b2748aec8410be005ddddb647)
BibTeX
@misc{dc07ea80057def,
  title = {Immunotherapy in Early Parkinson's Disease: A Biomarker-Driven Trial Framework for Secondary Prevention — Europe PMC PMID:41195411},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41195411},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_07ea80057def; sha256 2ee903b5ffa9ac5063a90400da645ee13cb6180b2748aec8410be005ddddb647},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41195411. Agents can read the archived copy with the MCP tool read_document.